目的: 探讨免疫毒素BDI-1-PEA 特异杀伤膀胱癌细胞的体外及体内研究。方法: 应用MTT法检测不同浓度的BDI-1-PEA，BDI-1和PEA的混合物（BDI-1+PEA），PEA对体外癌细胞的杀伤能力。接种于裸鼠背部皮下的癌细胞长至03 cm大小实体瘤时，于尾静脉隔日分别注入BDI-1-PEA、BDI-1、正常小鼠IgG共6次，观察不同的药物对癌的抑制作用。结果: 免疫毒素BDI-1-PEA在体外抗膀胱癌细胞系E-J的作用明显优于PEA及BDI-1与PEA的混合物，在荷瘤裸鼠体内明显优于BDI-1及IgG，与对非靶细胞的细胞毒性作用相比较差异非常显著。结论：免疫毒素BDI-1-PEA是一种很有潜力的抗癌药物，为进一步临床研究奠定基础。

Objective:To study the selective killing effects of immunotoxin BDI-1-PEA against human-bladder cancer cell line E-J and nude mice bearing human bladder tumor. Methods:MTT was used to measure the killing ratio of BDI-1-PEA, mixtures of BDI-1 and PEA, PEA against human-bladder cancer cell line E-J at different concentrations in vitro. When the tumor size reached 0.3 cm, BDI-1-PEA,BDI-1 and IgG were injected respectively to each group of mice though tail vein every other day for 6 times. Determined the inhibitory effects of BDI-1-PEA, BDI-1 and IgG in nude mice bearing human bladder tumor. Results: The results indicated that BDI-1-PEA showed stronger cytotoxicity against human bladder cancer cell line E-J than PEA and mixtures of BDI-1 and PEA, and stronger cytotoxicity against nude mice bearing human bladder tumor than BDI-1 and IgG.Compared with cytotoxicity against non-target cell，the difference was significant (P<0.01). Conclusion: Immunotoxin BDI-1-PEA is a largely potential anticancer drug, the result is a good foundation for the further clinical study.

R735.7

江苏省教委自然科学基金资助项目（基金编码98KJB320007）